Kulakova O.G.,Russian National Research Medical University |
Tsareva E.Y.,Russian National Research Medical University |
Lvovs D.,State Research Institute for Genetics and Selection of Industrial Microorganisms |
Favorov A.V.,Johns Hopkins University |
And 2 more authors.
Pharmacogenomics | Year: 2014
Various diseases require the selection of preferable treatment out of available alternatives. Multiple sclerosis (MS), an autoimmune inflammatory/neurodegenerative disease of the CNS, requires long-term medication with either specific disease-modifying therapy (DMT) - IFN-β or glatiramer acetate (GA) - which remain the only first-line DMTs in all countries. A significant share of MS patients are resistant to treatment with one or the other DMT; therefore, the earliest choice of preferable DMT is of particular importance. A number of conventional pharmacogenetic studies performed up to the present day have identified the treatment-sensitive genetic biomarkers that might be specific for the particular drug; however, the suitable biomarkers for selection of one or another first-line DMT are remained to be found. Comparative pharmacogenetic analysis may allow the identification of the discriminative genetic biomarkers, which may be more informative for an a priori DMT choice than those found in conventional pharmacogenetic studies. The search for discriminative markers of preferable first-line DMT, which differ in carriage between IFN-β responders and GA responders as well as between IFN-β nonresponders and GA nonresponders, has been performed in 253 IFN-β-treated MS patients and 285 GA-treated MS patients. A bioinformatics algorithm for identification of composite biomarkers (allelic sets) was applied on a unified set of immune-response genes, which are relevant for IFN-β and/or GA modes of action, and identical clinical criteria of treatment response. We found the range of discriminative markers, which include polymorphic variants of CCR5, IFNAR1, TGFB1, DRB1 or CTLA4 genes, in different combinations. Every allelic set includes the CCR5 genetic variant, which probably suggests its crucial role in the modulation of the DMT response. Special attention should be given to the (CCR5 d+ IFNAR1 G) discriminative combination, which clearly points towards IFN-β treatment choice for carriers of this combination. As a whole the comparative approach provides an option for the identification of prognostic composite biomarkers for a preferable medication among available alternatives. © 2014 Future Medicine Ltd.
Debabov V.G.,State Research Institute for Genetics and Selection of Industrial Microorganisms
Applied Biochemistry and Microbiology | Year: 2010
Deep desulfurization of oil and its fractions is currently performed by hydration at high temperature and hydrogen pressure, which makes the process rather expensive. Searches for alternative modes for desulfurization, among which is biodesulfurization, are intensely in progress. In this review, the following subjects are discussed: microorganisms capable of desulfurizing petroleum products, mechanisms of their activity, achievements in the field of process development, and disadvantages of the method. The existing level of knowledge is insufficient for immediate implementation of an industrial biotechnological process for sulfur elimination from oil and motor fuel and it can only be regarded as a medium-term (10-15 years) prospect. © 2010 Pleiades Publishing, Ltd.
Moisenovich M.M.,Moscow State University |
Pustovalova O.L.,Moscow State University |
Yu Arhipova A.,Moscow State University |
Vasiljeva T.V.,Moscow State University |
And 6 more authors.
Journal of Biomedical Materials Research - Part A | Year: 2011
The goal of this study was to generate porous scaffolds from the genetically engineered protein, an analogue of Nephila clavipes spidroin 1 (rS1/9) and to assess the properties of new rS1/9 scaffolds essential for bioengineering. The salt leaching technique was used to make the rS1/9 scaffolds of interconnected macroporous structure with spontaneously formed micropores. The tensile strength of scaffolds was 18 ± 5 N/cm2. Scaffolds were relatively stable in a phosphate buffer but degraded in oxidizing environment after 11 weeks of incubation. Applicability of the recombinant spidroin 1 as a substrate for cell culture was demonstrated by successful 3T3 cells growth on the surface of rS1/9 films (270 ± 20 cells/mm2 vs. 97 ± 8 cells/mm2 on the glass surface, p < 0.01). The 3T3 fibroblasts readily proliferated within the rS1/9 scaffold (from initially plated 19 ± 2 cells/mm3 to 3800 ± 304 cells/mm 3 after 2 weeks). By this time, cells were uniformly distributed between the surface and deeper layers (27% ± 8% and 33% ± 4%, respectively; p > 0.05), whereas the initial distribution was 58% ± 7% and 11% ± 8%, respectively; p < 0.05). The rS1/9 scaffolds implanted subcutaneously into Balb/c mice were well tolerated. Over a 2-month period, the scaffolds promoted an ingrowth of de novo formed vascularized connective tissue elements and nerve fibers. Thus, scaffolds made of the novel recombinant spidroin 1 analogue are potentially applicable in tissue engineering. © 2010 Wiley Periodicals, Inc.
Zubasheva M.V.,State Research Institute for Genetics and Selection of Industrial Microorganisms |
Ganushkina L.A.,Moscow Medical Academy |
Smirnova T.A.,State Research Institute for Genetics and Selection of Industrial Microorganisms |
Azizbekyan R.R.,State Research Institute for Genetics and Selection of Industrial Microorganisms
Applied Biochemistry and Microbiology | Year: 2011
Conditions for bioincapsulation of crystal-forming strain Brevibacillus laterosporus LAT 006 spores and crystals by using Tetrahymena pyriformis and Entamoeba moshkovskii Protozoa have been developed. Increase in the larvicidal activity of the incapsulated bacteria was demonstrated. Fractions of pure spores and crystals and intact spore-crystal preparation of LAT 006 were shown not to have toxic effect on the protozoa cells. © 2011 Pleiades Publishing, Ltd.
Tarutina M.G.,State Research Institute for Genetics and Selection of Industrial Microorganisms |
Dutova T.A.,State Research Institute for Genetics and Selection of Industrial Microorganisms |
Yezhova I.E.,State Research Institute for Genetics and Selection of Industrial Microorganisms |
Nishiuchi H.,Ajinomoto Co. |
Sineoky S.P.,State Research Institute for Genetics and Selection of Industrial Microorganisms
Journal of Bioscience and Bioengineering | Year: 2012
We identified Saccharomyces cerevisiae mutants with 100% higher intracellular glutathione using 1-methyl-3-nitro-1-nitrosoguanidine mutagenesis. This method employs visual selection of the most pigmented colonies among met30 strains carrying ade1 and ade2 mutations. Since the method does not involve genetic engineering, the mutants are suitable for use in the food industry. © 2012 The Society for Biotechnology, Japan.